Poxet represents a significant advancement in the pharmacological management of premature ejaculation (PE), offering men a targeted solution to improve ejaculatory latency and sexual satisfaction. This selective serotonin reuptake inhibitor (SSRI) is specifically formulated to address the neurochemical pathways involved in the ejaculatory reflex, providing a non-invasive treatment option for a condition affecting a substantial portion of the male population. With its well-documented efficacy profile and physician-recommended status, Poxet stands as a cornerstone in evidence-based sexual medicine, enabling clinicians to offer personalized treatment plans that align with contemporary urological and psychiatric guidelines for ejaculatory dysfunction.

Features

• Contains Dapoxetine hydrochloride as the active pharmaceutical ingredient (API)
• Available in 30mg and 60mg delayed-release tablet formulations
• Rapid onset of action with peak plasma concentrations achieved within 1-2 hours
• Short elimination half-life (approximately 15 hours) minimizing next-day residual effects
• Manufactured in cGMP-compliant facilities with rigorous quality control standards
• Bioequivalent to reference listed drugs with consistent pharmacokinetic profile
• Child-resistant blister packaging ensuring medication safety
• Temperature-stable formulation maintaining potency under recommended storage conditions

Benefits

• Significantly increases intravaginal ejaculatory latency time (IELT) by 3-4 fold compared to placebo
• Provides predictable control over ejaculation timing, reducing anxiety related to sexual performance
• Enhances sexual satisfaction for both partners through improved sexual endurance
• Allows for spontaneous sexual activity due to on-demand dosing regimen without daily medication commitment
• Supports psychological well-being by addressing a key aspect of sexual health
• Integrates easily into comprehensive PE treatment plans alongside behavioral techniques

Common use

Poxet is indicated for the treatment of premature ejaculation in adult men aged 18-64 years. It is prescribed for men who meet the diagnostic criteria for lifelong or acquired PE, typically characterized by persistent or recurrent ejaculation occurring within approximately one minute of vaginal penetration (lifelong PE) or a clinically significant reduction in latency time (acquired PE). The medication is used on an as-needed basis approximately 1-3 hours before anticipated sexual activity, though optimal timing may vary based on individual pharmacokinetic factors. Clinical studies demonstrate its effectiveness across diverse patient populations, regardless of PE etiology, though best results are observed when combined with psychosexual counseling and partner communication strategies.

Dosage and direction

The recommended starting dose is 30mg taken orally with a full glass of water approximately 1-3 hours before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 60mg or decreased to 30mg. The tablet should be swallowed whole without crushing or chewing, and may be taken with or without food, though high-fat meals may delay absorption. Patients should not take more than one dose within any 24-hour period. Dose adjustment is recommended for patients with hepatic impairment (maximum 30mg dose) or those taking potent CYP3A4 inhibitors. Renal impairment does not significantly affect dapoxetine pharmacokinetics, though caution is advised in severe cases.

Precautions

Patients should be screened for underlying cardiovascular conditions before initiation, as SSRIs may cause orthostatic hypotension. Those with history of syncope or predisposing conditions should use with particular caution. Monitoring for mood changes, including emerging anxiety, agitation, or suicidal ideation, is recommended, particularly in younger patients. Avoid alcohol consumption while taking Poxet due to increased risk of adverse neurocognitive and cardiovascular effects. Patients should be advised about the potential for dizziness and syncope, particularly during the first few hours after dosing. Those with conditions that might predispose to hypotension (dehydration, hypovolemia) should ensure adequate fluid intake.

Contraindications

Poxet is contraindicated in patients with known hypersensitivity to dapoxetine or any excipients in the formulation. It must not be used in combination with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy due to risk of serotonin syndrome. Concurrent use with thioridazine is prohibited. Patients with significant hepatic impairment (Child-Pugh class C) should not use this medication. Those with history of mania or severe depression should avoid Poxet until stabilized. The medication is contraindicated in patients with established cardiovascular disease including heart failure, conduction abnormalities, or significant ischemic heart disease.

Possible side effects

Common adverse reactions (≥1%) include nausea (8.7-20.1%), dizziness (6.2-10.9%), headache (5.6-8.8%), diarrhea (3.9-6.8%), insomnia (2.3-4.0%), and fatigue (2.1-3.7%). Less frequently reported effects include orthostatic hypotension (0.6-2.6%), syncope (0.06-0.23%), blurred vision (0.8-1.9%), and tinnitus (0.4-1.1%). Most side effects are mild to moderate in intensity and tend to decrease in frequency with continued use. Serious but rare adverse events include serotonin syndrome, prolonged erection, and angle-closure glaucoma. Patients should report any persistent or concerning symptoms to their healthcare provider.

Drug interaction

Poxet undergoes extensive hepatic metabolism primarily via CYP3A4, CYP2D6, and flavin-containing monooxygenase systems. Potent CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase dapoxetine exposure approximately 3-4 fold—concomitant use requires dose reduction to 30mg maximum. Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem) may also increase exposure. Concurrent use with serotonergic drugs (tramadol, linezolid, lithium, triptans) increases serotonin syndrome risk. CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) may modestly increase exposure. Poxet may potentiate effects of alcohol and other CNS depressants. Caution advised with alpha-adrenergic blockers due to potential additive vasodilatory effects.

Missed dose

As Poxet is taken on an as-needed basis rather than on a scheduled regimen, the concept of a “missed dose” does not apply in the conventional sense. If a patient forgets to take the medication before sexual activity, they should not take it afterward. The next dose may be taken when needed for subsequent sexual activity, maintaining the minimum 24-hour interval between doses. Patients should not double the dose to make up for a missed administration, as this significantly increases the risk of adverse effects without providing additional therapeutic benefit.

Overdose

Symptoms of overdose may include serotonin syndrome (agitation, confusion, diaphoresis, tachycardia, hyperthermia, neuromuscular abnormalities), syncope, dizziness, nausea, vomiting, and somnolence. There is no specific antidote for dapoxetine overdose. Treatment should consist of general supportive measures including monitoring of vital signs and ECG. Gastric lavage may be considered if performed soon after ingestion. Activated charcoal may be administered. Patients should be monitored for at least 24 hours due to the drug’s pharmacokinetic profile. Serotonin syndrome should be managed with supportive care and may require cyproheptadine in severe cases.

Storage

Store at room temperature between 15-30°C (59-86°F) in the original blister packaging to protect from moisture and light. Keep the medication in a secure location out of reach of children and pets. Do not transfer tablets to alternative containers as this may compromise stability and increase risk of accidental ingestion. Do not use if the blister packaging is damaged or tablets show signs of deterioration. Properly dispose of expired or unused medication through medication take-back programs or according to local regulations—do not flush down toilets or pour into drains.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Poxet is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual results may vary based on numerous factors including patient physiology, adherence to dosing instructions, and presence of comorbid conditions. Patients should consult with their healthcare provider for proper diagnosis and treatment recommendations. The manufacturer is not liable for any adverse outcomes resulting from improper use, self-diagnosis, or failure to follow prescribed instructions.

Reviews

Clinical trials involving over 6,000 patients demonstrate consistent efficacy, with study participants reporting 2.5-3.0 fold increases in IELT and significant improvements in perceived control over ejaculation and sexual satisfaction. In a 12-week, double-blind, placebo-controlled study, mean IELT increased from 0.9 minutes at baseline to 3.1 minutes with 30mg and 3.6 minutes with 60mg, compared to 1.9 minutes with placebo. Patient-reported outcomes showed 2.5-3.2 point improvements on the Premature Ejaculation Profile measures. Real-world evidence from post-marketing surveillance supports these findings, with 78% of patients reporting meaningful improvement in ejaculatory control and 72% reporting enhanced sexual satisfaction after 3 months of use under medical supervision.